Literature DB >> 2213834

Imidazodiazepinediones: a new class of adenosine receptor antagonists.

J W Daly1, I Hide, P K Bridson.   

Abstract

A series of imidazo[4,5-e][1-4]diazepine-5,8-diones were synthesized from hypoxanthines. Certain of these cyclic homologues of caffeine, theophylline, theobromine, 3-isobutyl-1-methylxanthine, and enprofylline were inhibitors of binding of adenosine analogues to rat brain A1 and A2 adenosine receptors and were antagonists of A2 adenosine receptors stimulatory to adenylate cyclase in rat PC12 cell membranes. Activity at adenosine receptors was lower than the corresponding xanthines, perhaps because imidazodiazepinediones contain a boat-shaped seven-membered ring rather than the planar heteroaryl ring system of the xanthines. The imidazodiazepinediones had low affinity for brain benzodiazepine sites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213834     DOI: 10.1021/jm00172a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  A binding site model and structure-activity relationships for the rat A3 adenosine receptor.

Authors:  P J van Galen; A H van Bergen; C Gallo-Rodriguez; N Melman; M E Olah; A P IJzerman; G L Stiles; K A Jacobson
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

Review 2.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

Review 3.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

Review 4.  Xanthine scaffold: scope and potential in drug development.

Authors:  Nivedita Singh; Ashwinee Kumar Shreshtha; M S Thakur; Sanjukta Patra
Journal:  Heliyon       Date:  2018-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.